The Japan Syringe market is forecast to grow at a CAGR of 4.1%, reaching USD 0.60 billion in 2031 from USD 0.49 billion in 2026.
Structural demand in the Japanese syringe market is anchored in the nation’s advanced chronic disease management framework and its world-leading elderly population ratio. Unlike short-term consumption spikes associated with seasonal vaccination campaigns, the underlying demand is sustained by the high prevalence of non-communicable diseases such as diabetes and cardiovascular conditions that require consistent, long-term injectable therapies. The industry is characterized by a high dependency on the domestic pharmaceutical sector, specifically the rising utilization of biologics and biosimilars which necessitate sophisticated primary packaging and delivery systems to maintain drug stability.
Technology and process evolution in the Japanese market are increasingly focused on the refinement of the "patient experience" and operational safety. This is evidenced by the adoption of silicone-free coatings to prevent plunger stiction and the development of auto-retractable needle mechanisms. Furthermore, the sustainability transition is beginning to influence procurement, with the Japanese Ministry of the Environment encouraging the medical device industry to explore bio-based polymers and improved incineration recyclability. The strategic importance of the syringe market is magnified by Japan’s stringent PMDA (Pharmaceuticals and Medical Devices Agency) standards, which prioritize precision engineering and high-purity materials to prevent leachables and extractables from compromising patient safety.
Aging Demographic and Chronic Disease Prevalence: Japan's population over age 65 has surpassed 29%, leading to a direct increase in the volume of daily subcutaneous injections for conditions such as diabetes and osteoporosis, which fundamentally drives demand for high-precision insulin and smaller-volume syringes.
Adoption of Biologics and Specialty Medicines: The rise of complex protein-based therapies requires sophisticated delivery systems; consequently, the market is seeing increased demand for glass and specialized plastic syringes that offer low reactivity and high gas barrier properties.
Stringent Occupational Safety Standards: Japanese medical institutions are increasingly enforcing the use of safety-engineered devices to comply with national labor safety guidelines aimed at eliminating accidental needlestick injuries, which shifts the market away from basic conventional designs.
Advancements in Home-Based Healthcare: As the Japanese government promotes community-based integrated care (Chiiki Hokatsu Care System), there is a structural surge in demand for easy-to-use, ergonomic syringes designed for non-professional caregivers and patient self-administration.
National Health Insurance (NHI) Pricing Pressures: Frequent government-mandated price cuts for medical consumables can compress profit margins for manufacturers, acting as a restraint on the widespread adoption of higher-cost, specialized syringe technologies.
Strict Regulatory Hurdles for Material Innovation: The lengthy and costly clinical evidence requirements for new bio-based materials can delay the market entry of "green" syringes, presenting a challenge to sustainability goals.
Growth in Minimally Invasive Procedures: The trend toward catheter-based and endoscopic surgeries presents an opportunity for specialized catheter tip and eccentric tip syringes designed for precision flushing and fluid management in surgical suites.
Digital Integration and Smart Syringes: An emerging opportunity exists for the integration of NFC (Near Field Communication) or QR-coded syringes to track medication adherence within Japan’s digitized health records system, facilitating better patient monitoring.
The pricing structure for syringes in Japan is fundamentally influenced by the duality of required materials. Plastic Syringes, the high-volume segment, rely on global petrochemical supply for medical-grade polypropylene and polyethylene. Pricing in this segment is highly sensitive to fluctuations in crude oil and polymer manufacturing capacity, placing downward pressure on margins. Conversely, the high-margin Glass segment is defined by the stability and purity of specialized borosilicate glass tubing, which commands a premium due to its critical role in ensuring the shelf-life and efficacy of sensitive biological drugs. This material demand mandates a secure, high-quality domestic or near-shore supply chain to avoid contamination and supply volatility.
The Japanese syringe supply chain is structured to ensure resilience and maintain stringent quality controls, characterized by a dual reliance model. While Japanese corporations like TERUMO and Nipro maintain advanced domestic and regional production centers, particularly for specialized products like Glass Prefillable Syringes, the volume supply of commodity Plastic Syringes often relies on offshore manufacturing hubs, primarily in Southeast Asia and Europe. Logistical complexities involve high-speed sterile packaging, adherence to strict cold chain requirements for pre-filled products, and navigating import regulations under the PMD Act. Key dependencies exist on global specialized material suppliers for high-purity glass and ultra-thin-wall needle cannula.
Jurisdiction | Key Regulation / Agency | Market Impact Analysis |
Japan | Pharmaceuticals and Medical Devices Act (PMD Act) / PMDA | Mandates Quality Standards: The PMD Act classifies syringes (Class I, II, III) based on risk, requiring stringent Marketing Authorization Holder (MAH) oversight and Quality Management System (QMS) adherence. This elevates the barrier to entry for foreign, low-cost manufacturers and drives domestic demand toward certified, high-quality products, especially those with advanced safety features. |
Japan | MHLW Notifications on Safety and Infection Control | Drives Safety Demand: MHLW mandates for enhanced safety protocols in hospitals, including the promotion of products designed to prevent needlestick injuries. This regulatory push creates specific, non-negotiable demand for Safety Syringes and auto-retractable needles, effectively shifting institutional procurement away from conventional, exposed-needle systems. |
Japan | MHLW / Japanese Industrial Standards (JIS) / ISO 80369 Series | Enforces Product Harmonization: The MHLW's integration of ISO standards, such as the ISO 80369 series for small-bore connectors (e.g., Luer connections), ensures non-interconnectability between different applications (e.g., enteral and intravenous). This mandate drives product obsolescence and creates accelerated demand for new, compliant Luer Lock Syringe and tip designs across all segments. |
November 2025: Kyowa Kirin announced the launch of its Crysvita (burosumab) prefilled syringe formulation in Japan. This new delivery system for the treatment of XLH (X-linked hypophosphatemia) aims to provide greater convenience and ease of administration for patients, potentially enhancing adherence to the chronic treatment.
July 2025: Celltrion launched Steqeyma® (CT-P43), a biosimilar to ustekinumab (Stelara®), in Japan. This injectable treatment for autoimmune conditions is provided in a syringe format, offering a more cost-effective alternative for conditions like psoriasis and psoriatic arthritis in the Japanese healthcare system.
September 2024: BD commercially released the Neopak™ XtraFlow™ Glass Prefillable Syringe, which features design enhancements for high-viscosity biologic drugs. Concurrently, BD integrated a high-volume manufacturing line in France, increasing the production capacity of the Neopak™ platform by sevenfold.
Th need for the classic Insulin Syringe in Japan is characterized by a secular decline, driven by the patient-centric pivot towards Insulin Pens and, increasingly, continuous glucose monitoring (CGM) systems that minimize the need for manual injection preparation. However, a significant, non-displacing niche demand persists. This residual growth is primarily sustained by specific clinical scenarios, such as neonatal care or pediatric patients requiring extremely low, precise dosing volumes (often smaller than a pen-device's minimum click), and in institutional settings where specific clinical dosing protocols preclude pen use. Furthermore, for cost-sensitive patient populations or those with limited access to insurance coverage for premium pen systems, the Insulin Syringe remains a necessary, affordable delivery option, maintaining a stable, albeit shrinking, volume floor within the market. Manufacturers must view this segment as a legacy product, focusing on cost-efficient production rather than innovative development.
The market profile for Glass syringes is intensely linked to the domestic growth of complex injectable pharmaceuticals, particularly high-value biologics, vaccines, and pre-filled emergency medications. The Material segment experiences elevated demand because borosilicate glass offers superior chemical compatibility and gas barrier properties compared to plastic, which is essential for preserving the potency and stability of sensitive protein-based drugs over long shelf lives. The glass material segment is driven by the strict requirement of pharmaceutical companies to minimize extractables, leachables, and silicone oil content (as seen with TERUMO's silicone oil-free products) to prevent protein aggregation. Consequently, the demand for Glass Prefillable Syringes is high-growth and strategically important, as pharmaceutical companies prioritize drug stability and regulatory acceptance over the lower cost of plastic alternatives, thereby commanding a higher unit price and margin in the Japanese market.
Smaller volume syringes (typically 1mL to 3mL) hold a dominant position in the Japanese market due to their widespread use in anesthetic administration, pediatric care, and high-precision diagnostic testing. The operational advantage of these syringes lies in their ability to deliver minute, highly accurate doses with minimal "dead space," which is crucial for expensive specialty medications where drug wastage must be minimized.
Terumo Corporation
Nipro Corporation
BD (Becton, Dickinson and Company)
B. Braun SE
Teleflex Incorporated
ICU Medical, Inc.
Advin Health Care
Healthcare Technologies
Eisai Co., Ltd.
JMS Co., Ltd.
Terumo holds a preeminent market position in Japan, particularly in the hospital and home-care segments. Its strategy is focused on "Global Management," integrating its Kofu production base with worldwide R&D to lead in safety-engineered devices and pre-filled systems. Terumo’s competitive advantage lies in its proprietary needle-thinning technology and its deep integration with the Japanese clinical community, allowing for rapid feedback-driven product iteration. Its geographic strength is absolute in the domestic market, supplemented by a significant footprint in Europe and North America.
Nipro is a diversified medical manufacturer with a significant focus on dialysis and injection systems. Its strategy emphasizes cost-efficiency through high-volume automated manufacturing and a global production network. Nipro’s competitive advantage is its ability to supply high volumes of conventional and safety syringes while maintaining strict quality controls. Its technology differentiation is seen in its glass manufacturing division, which provides high-purity glass for its own pre-filled syringe lines, creating a highly integrated and resilient supply chain.
BD is the leading global player with a strong presence in the Japanese market through its BD Medical division. Its strategy centers on innovation in safety-engineered devices and the expansion of its pre-fillable syringe portfolio to support the pharmaceutical industry. BD’s competitive advantage in Japan is its global R&D scale and its reputation for high-reliability immunization devices. The company differentiates itself through sophisticated "Safety-Lok" and auto-disable technologies that align perfectly with Japan’s stringent infection control mandates.
Japan's syringe market is structurally driven by an aging population and a shift toward safety-engineered and pre-filled systems. Despite NHI pricing pressures, demand for high-precision, patient-centric delivery devices remains robust, fueled by biotechnology advancements and home-care integration.
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 0.49 billion |
| Total Market Size in 2031 | USD 0.60 billion |
| Forecast Unit | Billion |
| Growth Rate | 4.1% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Type, Material, Syringe Size |
| Companies |
|